soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo soul trial oral semaglutide cardiovascular
Pay in 4 interest-free payments of $7.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22





:max_bytes(150000):strip_icc():focal(745x340:747x342)/Donna-DiCarlo-081525-6f9905b921994e25bd6b3c2bdd6ced58.jpg)

















